Vedrana Milić-Rašić

Vedrana Milić-Rašić

Auto-generated profile, based on publicly available information

Vedrana Milić-Rašić

Medicinski fakultet Univerziteta u Beogradu Beograd

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2006 in Acta Radiologica
Verified
Journal Article
Closed access
DKDusko Kozic
Dusko Kozic
MNM. Nagulic
M. Nagulic
JOJelena Ostojic
Jelena Ostojic
MSM. Samardzic
M. Samardzic
VMV. Milic-Rasic
V. Milic-Rasic
RSR. Nuri Sener
R. Nuri Sener
We present the short-term follow-up magnetic resonance (MR) studies and 1H-MR spectroscopy in a child with malignant peripheral nerve sheath tumor of the oculomotor nerve associated with other less aggressive cranial nerve schwannomas. The tumor revealed perineural extension and diffuse nerve involvement besides rapid growth. 1H-MR spectroscopy was helpful in excluding an intra-axial neoplasm with exophytic growth, mainly due to the absence of creatine and N-acetyl aspartate peaks, and markedly elevated choline peak.

1 January 2015 in Materia Medica
Verified
Journal Article
Open access
PDF file
MKMarija Knežević
Marija Knežević
JMJelena Mladenović
Jelena Mladenović
GKGordana Kovacevic
Gordana Kovacevic
SOSlavica Ostojić
Slavica Ostojić
JMJelena Milin-Lazovića
Jelena Milin-Lazovića
VMVedrana Milić-Rašić
Vedrana Milić-Rašić
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive skeletal muscle denervation due to deterioration of the alpha-motoneurons and consequently by the occurrence of hypotonia, muscle weakness, atrophy. The aim of our research is to demonstrate the potential impact of SMN2 gene copies on the development of one of the three types of SMA patients in the period from 2001 to 2013 year. The study included 74 patients (44 females and 30 males) fulfilling clinical diagnostic criteria for SMA. The patients were classified in a particular category of SMA (type 1, 2 or 3). Ability to sit/walk unaided was taken as the main criterion in the patient classification. 8 patients were classified as type 1 (11.3%), 27 as type 2 (38%), while 36 (50.7%) as type 3 of SMA. Homozygous gene deletions SMN1 was represented in 72/74 (97.2%) of the patients. Remaining two patients are compound heterozygotes with an absence of one SMN1 allele and a small mutation in the other. The number of SMN2 gene copies was significantly lower in SMA type 1 patients than in SMA type 2 and type 3 patients, which showed a highly statistically significant difference (p < 0.001). In this study we found that the number of copies of SMN2 gene correlated with the phenotype of SMA patients by decreasing the severity, which can be used as one of the indispensable prognostic parameters of disease.

1 January 2023 in Medicinski podmladak
Verified
Journal Article
Open access
PDF file
AKAna Kosac
Ana Kosac
VMVedrana Milić-Rašić
Vedrana Milić-Rašić
DSDusanka Savic-Pavicevic
Dusanka Savic-Pavicevic
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
Duchenne muscular dystrophy is the most common inherited muscle disease in childhood, which has a progressive clinical course with a fatal outcome that most often occurs between the second and fourth decade of life. The disease is inherited X-linked, recessively, and in two-thirds of patients, it is transmitted from the mother, while in the remaining third of patients, it is a de novo mutation. Mutations in the dystrophin gene (DMD gene) such as deletions, duplications and small mutations can be found throughout the entire length of the gene. The disease begins between the third and fifth year of life, and the initial muscle weaknesses are clinically manifested as slower running, difficulty climbing stairs or difficulty getting up from squats. Sometimes, accidentally discovered, elevated keratin kinase values or delayed early psychomotor development milestones in a child with hypertrophic calves can initiate a diagnostic procedure in the direction of Duchenne muscular dystrophy. The disease usually has a uniform clinical course and implies a clear time sequence of events. Muscle weakness leads to loss of ambulation, then the function of the upper extremities, to complete immobility, with the evolution of dilated cardiomyopathy and respiratory insufficiency, which are the main causes of death. Certain patients show deviations from the above in terms of longer functionality and later loss of independent ambulation, later cardiomyopathy and respiratory insufficiency and vice versa. It is believed that in addition to the application of modern standards of care and treatment of patients, the clinical course is influenced by genes independent of the causal DMD gene, which affects processes in dystrophic muscle, primarily inflammation, fibrosis and fatty infiltration, through specific signaling pathways. So far, six genes have been described whose variants modify the course of Duchenne muscular dystrophy. The secreted phosphoprotein 1 (SPP1) is the first described gene whose G allele in the variant rs28357094 is associated with an earlier age of gait loss. In addition, variants in the genes described are LTBP4 (latent transforming growth factor-b binding protein 4), CD40, ACTN3 (actinin 3), THBS1 (thrombospondin 1) and TCTEX1D1 (Tctex1 domain containing 1). The aim of this paper is to present already-known genes that modify Duchenne muscular dystrophy and their influence on the clinical course of the disease.